Higashi Eriko, Nakajima Miki, Katoh Miki, Tokudome Shogo, Yokoi Tsuyoshi
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Drug Metab Dispos. 2007 Apr;35(4):508-14. doi: 10.1124/dmd.106.014084. Epub 2007 Jan 19.
Human CYP2A6 catalyzes the metabolism of nicotine, cotinine, and coumarin as well as some pharmaceutical drugs. CYP2A6 is highly expressed in liver and, also, in brain and steroid-related tissues. In this study, we investigated the inhibitory effects of neurotransmitters and steroid hormones on CYP2A6 activity. We found that coumarin 7-hydroxylation and cotinine 3'-hydroxylation by recombinant CYP2A6 expressed in baculovirus-infected insect cells were competitively inhibited by tryptamine (both K(i) = 0.2 microM), serotonin (K(i) = 252 microM and 167 microM), dopamine (K(i) = 49 microM and 22 microM), and histamine (K(i) = 428 microM and 359 microM). Cotinine formation from nicotine was inhibited by tryptamine (K(i) = 0.7 microM, competitive), serotonin (K(i) = 272 microM, noncompetitive), dopamine, noradrenaline, and adrenaline (K(i) = 11 microM, 54 microM, and 81 microM, uncompetitive). Estrogens (K(i) = 0.6-3.8 microM), androgens (K(i) = 60-149 microM), and corticosterone (K(i) = 36 microM) also inhibited cotinine formation, but coumarin 7-hydroxylation and cotinine 3'-hydroxylation did not. Nicotine-Delta(5'(1'))-iminium ion formation from nicotine was not affected by these steroid hormones, indicating that the inhibition of cotinine formation was due to the inhibitory effects on aldehyde oxidase. The nicotine-Delta(5'(1'))-iminium ion formation was competitively inhibited by tryptamine (K(i) = 0.3 microM), serotonin (K(i) = 316 microM), dopamine (K(i) = 66 microM), and histamine (K(i) = 209 microM). Thus, we found that some neurotransmitters inhibit CYP2A6 activity, being related with inter- and intraindividual differences in CYP2A6-dependent metabolism. The inhibitory effects of steroid hormones on aldehyde oxidase may also contribute to interindividual differences in nicotine metabolism.
人细胞色素P450 2A6(CYP2A6)催化尼古丁、可替宁和香豆素以及一些药物的代谢。CYP2A6在肝脏中高度表达,在脑和类固醇相关组织中也有表达。在本研究中,我们研究了神经递质和类固醇激素对CYP2A6活性的抑制作用。我们发现,杆状病毒感染昆虫细胞中表达的重组CYP2A6催化的香豆素7-羟基化和可替宁3'-羟基化受到色胺(两者K(i)=0.2微摩尔)、5-羟色胺(K(i)=252微摩尔和167微摩尔)、多巴胺(K(i)=49微摩尔和22微摩尔)和组胺(K(i)=428微摩尔和359微摩尔)的竞争性抑制。尼古丁生成可替宁受到色胺(K(i)=0.7微摩尔,竞争性)、5-羟色胺(K(i)=272微摩尔,非竞争性)、多巴胺、去甲肾上腺素和肾上腺素(K(i)=11微摩尔、54微摩尔和81微摩尔,非竞争性)的抑制。雌激素(K(i)=0.6 - 3.8微摩尔)、雄激素(K(i)=60 - 149微摩尔)和皮质酮(K(i)=36微摩尔)也抑制可替宁生成,但不抑制香豆素7-羟基化和可替宁3'-羟基化。尼古丁生成尼古丁-Δ(5'(1'))-亚铵离子不受这些类固醇激素影响,表明可替宁生成的抑制是由于对醛氧化酶的抑制作用。尼古丁-Δ(5'(1'))-亚铵离子生成受到色胺(K(i)=0.3微摩尔)、5-羟色胺(K(i)=316微摩尔)、多巴胺(K(i)=66微摩尔)和组胺(K(i)=209微摩尔)的竞争性抑制。因此,我们发现一些神经递质抑制CYP2A6活性,这与CYP2A6依赖性代谢的个体间和个体内差异有关。类固醇激素对醛氧化酶的抑制作用也可能导致尼古丁代谢的个体间差异。